Clinical Trial Update: Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3 [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating safety and immunogenicity of two live, attenuated oral Shigella Sonnei vaccines, WRSs2 and WRSs3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Shigellosis

Drugs mentioned

• WRSs2
• WRSs3

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Shigella Infection | Phase 1 | Status: COMPLETED